Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G1 to S phase transition protein 1 homolog (GSPT1), also known as eRF3a, is a GTPase that plays a fundamental role in eukaryotic protein translation termination. It forms a complex with eRF1 to recognize stop codons and facilitate the release of nascent polypeptide chains from the ribosome (UniProt P15170). Beyond translation, GSPT1 is involved in regulating the transition of cells from the G1 to the S phase of the cell cycle and contributes to the control of mRNA stability. In recent years, GSPT1 has gained significant attention as a therapeutic target in oncology, particularly for acute myeloid leukemia (AML), due to its susceptibility to targeted protein degradation. Molecular glue degraders, such as CC-90009, recruit GSPT1 to the CRL4-CRBN E3 ubiquitin ligase complex, leading to its polyubiquitination and subsequent proteasomal degradation, which triggers rapid apoptosis in MYC-driven cancer cells (Surka et al., 2021, Nature Communications).
Targeted protein degradation via molecular glue recruitment to the CRL4-CRBN E3 ubiquitin ligase complex.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G1 to S phase transition protein 1 homolog (GSPT1).